DOCSLIB.ORG

Influenza: Questions and Answers Information About the Disease and Vaccines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Influenza: Questions and Answers Information About the Disease and Vaccines Influenza: Questions and Answers information about the disease and vaccines What causes influenza? cially older adults. Some people may also have nausea, Influenza is caused by influenza viruses. Two types of vomiting, or diarrhea; these symptoms are more often influenza, A and B, cause outbreaks in people. Both seen in children. types can cause mild to severe illness in all age groups. While influenza A viruses infect humans and other ani- How serious is influenza? mals, influenza B viruses affects only humans. Although many people think of influenza as just a com- Subtypes of type A influenza virus are identified by two mon cold, it is really a specific and serious respiratory antigenic proteins called hemagglutinin [H] and neur- infection that can result in hospitalization and death. aminidase [N] on the surface of the virus. These proteins Rates of infection from seasonal influenza are highest can change, or mutate, over time. Because these pro- among children. The risks for influenza-related compli- teins can change, people can get influenza infections cations, hospitalizations, and deaths are highest multiple times over their lifetime. An antigen “shift” among adults ages 65 years and older, children (major change) creates a new influenza A virus with a younger than 5 years, pregnant women, and people of new H, or H and N, that can cause a global epidemic if any age who have medical conditions that place them the virus can spread easily among people and if most at increased risk for complications from influenza. people do not have immunity against it. This happened From the 2010–11 through 2019–20 seasons, the most recently in 2009 when the novel H1N1 influenza annual influenza-related disease burden varied from virus appeared and led to a major pandemic. 9–49 million illnesses, 4–23 million medical visits, 140,000–960,000 hospitalizations, and 12,000–61,000 How does influenza spread? deaths per year. The number of influenza laboratory- Influenza is transmitted through the air from the respi- confirmed deaths in children reported to CDC aver- ratory tract of an infected person when they talk, aged 132 (range 37–189) per year. This is considered cough, or sneeze. It can also be transmitted by touch- an underestimate of actual pediatric deaths as some ing a surface that has respiratory droplets with influ- influenza-related deaths are likely not reported or rec- enza viruses and then touching the nose, mouth, or ognized. For more information on the health burden of possibly eyes. influenza, see www.cdc.gov/flu/about/burden/index.html. How long does it take to develop symptoms of influenza after being exposed? What are possible complications from influenza? The most frequent complication from influenza are viral The incubation period of influenza is usually two days and bacterial pneumonia. Other complications include but can range from one to four days. inflammation of the heart (myocarditis), brain (enceph- alitis) or muscle (myositis). Influenza also can worsen What are the symptoms of influenza? chronic medical conditions like cardiovascular disease, Typical influenza disease is characterized by sudden leading to heart attacks or worsening congestive heart onset of fever, aching muscles, sore throat, and non- failure, and worsening asthma and diabetes. productive cough. Additional symptoms may include Reye syndrome is a complication that occurs almost runny nose, headache, a burning sensation in the exclusively in children – patients suffer from severe chest, and eye pain and sensitivity to light. Typical vomiting and confusion, which may progress to coma influenza disease does not occur in every infected per- because of swelling of the brain. To decrease the chance son. Someone who has been previously exposed to of developing Reye syndrome, infants, children, and similar virus strains (through natural infection or vacci- teenagers should not be given aspirin for fever reduction nation) is less likely to develop serious clinical illness. or pain relief. Not everyone with influenza illness has a fever, espe- continued on the next page � Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org www.immunize.org/catg.d/p4208.pdf • Item #P4208 (10/20) Influenza: Questions and Answers (continued) page 2 of 7 What is the best way to prevent influenza? used for both treatment and prevention (also called The best way to prevent influenza is with annual prophylaxis). It is important to remember that antiviral influenza vaccination. drugs are not a substitute for vaccination. CDC has more information on the use of influenza antiviral Is there an alternative to vaccination in preventing medications at www.cdc.gov/flu/professionals/antivirals/index.htm. influenza? No. Vaccination is the single best way to prevent influ- If I contract influenza, what should I do? enza and its complications. Some steps that may help Call your healthcare provider to discuss your particular prevent the spread of respiratory illnesses, like influ- situation. If you are at high risk of developing complica- enza, include: tions from influenza, you should consult your health- care provider immediately if you develop influenza-like 1. Cover your nose and mouth with your sleeve or a symptoms; you may benefit from influenza antiviral tissue when you cough or sneeze – throw the tissue medicine. You will need to get plenty of rest and drink away after you use it and then wash your hands. a lot of liquids. You can also take medications to 2. Wash your hands often with soap and water, especially relieve the symptoms of influenza (but never give aspi- after you cough or sneeze. If you are not near water, rin to children or teenagers who have influenza-like use an alcohol-based hand cleaner. symptoms, particularly fever). Antiviral medicines are 3. Stay away as much as you can from people who are most beneficial when started within the first 1–2 days sick. of influenza illness. For purposes of treatment and pre- 4. If you get influenza, stay home from work or school vention, antiviral medicines are prioritized for people for at least 24 hours after the fever has ended. If you at high risk for influenza-related complications, such as are sick, don’t go near other people to avoid infect- people 65 years or older, people with chronic medical ing them. conditions, pregnant women, and young children. 5. Try not to touch your eyes, nose, or mouth. Viruses When is a person with influenza contagious? often spread this way. A person may pass virus from 1 day before symptoms Are any drugs available to prevent or treat influenza? start through 5–7 days after illness onset. There are four influenza antiviral drugs recommended Can you get influenza more than once? for use in selected patients. Oseltamivir (Tamiflu) and inhaled zanamivir (Relenza) can be used for treatment Yes. Influenza viruses change frequently and infection or prevention. Oral baloxavir (Xofluza) and intravenous with one strain does not provide protection against peramivir (Rapivab) are recommended only for treat- all strains. ment. All four provide protection against both A and B viruses. Two other antiviral medications, amantadine When did influenza vaccine first become available? and rimantadine which have activity only against influ- The first influenza vaccine in the United States became enza A viruses, are not recommended for use because available in 1945. of high levels of resistance among circulating influenza A viruses. What kind of vaccine is it? Use of antiviral medications can reduce the severity The most common influenza vaccine is made from and length of influenza illness. People with severe ill- inactivated (killed) viruses that are given as an intra- ness and people at increased risk of severe illness muscular injection. Two different influenza vaccines (e.g., people at high risk of influenza complications, (cell-culture based inactivated vaccine and recombi- such as young children, people with chronic medical nant influenza vaccine or RIV) are made without the conditions, and older adults) should be treated with use of eggs. A nasal spray influenza vaccine containing influenza antiviral medications when influenza is live viruses that have been weakened (attenuated) is suspected. also available. Influenza vaccine in the United States Antiviral medicine is also recommended for use in cer- contains either 3 or 4 strains of influenza virus. There tain outbreak situations (e.g., nursing home out- is no preference for one type of vaccine over another breaks); in such cases, antiviral medication can be for people for whom more than one recommended and age-appropriate vaccine is available. continued on the next page � Immunization Action Coalition • Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org www.immunize.org/catg.d/p4208.pdf • Item #P4208 (10/20) Influenza: Questions and Answers (continued) page 3 of 7 How are the vaccines made? cine. Children age 2 years and older can receive Flu- Every year, manufacturers develop and produce vaccine Mist if they do not have contraindications to FluMist. that contains virus strains that World Health Organiza- tion and, in the U.S., the FDA and CDC believe are Who recommends the influenza vaccine? most likely to circulate during the upcoming influenza The Centers for Disease Control and Prevention, the season. Influenza vaccines contain both type A and type American Academy of Pediatrics, the American Acad- B viruses. emy of Family Physicians, the American College of Phy- For the inactivated (injectable) vaccine, the viruses sicians, the American College of Obstetricians and are inactivated (killed), purified, and packaged in vials Gynecologists, and the American College of Nurse Mid- or syringes. Live attenuated influenza virus vaccine is wives all recommend influenza vaccine. packaged in a special nasal sprayer. Recombinant tech- nology is used to make recombinant influenza vaccine; How often should this vaccine be given? this vaccine only includes one part of the influenza virus, Influenza vaccine is given each year because immunity the hemagglutinin, in the vaccine.
Load more

Recommended publications
  • Dectova, INN-Zanamivir
    28 February 2019 EMA/CHMP/851480/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report DECTOVA International non-proprietary name: zanamivir Procedure No. EMEA/H/C/004102/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Steps taken for the assessment of the product ......................................................... 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ......................................................................................... 12 2.1.2. Epidemiology .................................................................................................. 12 2.1.3. Biologic features .............................................................................................
    [Show full text]
  • Influenza Virus Infections in Humans October 2018
    Influenza virus infections in humans October 2018 This note is provided in order to clarify the differences among seasonal influenza, pandemic influenza, and zoonotic or variant influenza. Seasonal influenza Seasonal influenza viruses circulate and cause disease in humans every year. In temperate climates, disease tends to occur seasonally in the winter months, spreading from person-to- person through sneezing, coughing, or touching contaminated surfaces. Seasonal influenza viruses can cause mild to severe illness and even death, particularly in some high-risk individuals. Persons at increased risk for severe disease include pregnant women, the very young and very old, immune-compromised people, and people with chronic underlying medical conditions. Seasonal influenza viruses evolve continuously, which means that people can get infected multiple times throughout their lives. Therefore the components of seasonal influenza vaccines are reviewed frequently (currently biannually) and updated periodically to ensure continued effectiveness of the vaccines. There are three large groupings or types of seasonal influenza viruses, labeled A, B, and C. Type A influenza viruses are further divided into subtypes according to the specific variety and combinations of two proteins that occur on the surface of the virus, the hemagglutinin or “H” protein and the neuraminidase or “N” protein. Currently, influenza A(H1N1) and A(H3N2) are the circulating seasonal influenza A virus subtypes. This seasonal A(H1N1) virus is the same virus that caused the 2009 influenza pandemic, as it is now circulating seasonally. In addition, there are two type B viruses that are also circulating as seasonal influenza viruses, which are named after the areas where they were first identified, Victoria lineage and Yamagata lineage.
    [Show full text]
  • STI Screening Timetable
    Patient Education Information from University Health Center’s STI Screening Clinic Page 1 of 1 STI Screening Timetable How long until STI (sexually transmitted infection) screening tests turn positive? How long until STI symptoms might show up? The time between infection and a positive test, or between infection and symptoms, is variable and depends on many factors, including the behavior of the infectious agent, how and where the body is infected, and the state of a person’s immune system and personal health. Many STIs don’t have any symptoms. The incubation period times listed in the chart below are averages only. If you have further questions or concerns, you can schedule an appointment with a clinician at 541-346-2770. STI screening test Window period (time from exposure until Incubation period (time between exposure and screening test turns positive) when symptoms appear) Chlamydia (urine specimen or swab of 1 week most of the time Often no symptoms vagina, rectum, throat) 2 weeks catches almost all 1-3 weeks on average Gonorrhea (urine specimen on swab of 1 week most of the time Often no symptoms, especially vaginal vagina, rectum, throat) 2 weeks catches almost all infections usually within 2-8 days but can be up to 2 weeks Syphilis (blood test, RPR) 1 month catches most Often symptoms too mild to notice 3 months catches almost all 10-90 days average 21 days HIV (oral cheek swab) 1 month catches most Sometimes mild body aches and fever within 1-2 3 months catches almost all weeks then can be months to years HIV (blood test, antigen/antibody
    [Show full text]
  • Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza
    Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza Aeron Hurt WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia www.influenzacentre.org NA inhibitor antiviral drugs Top view of NA NA inhibitor NA enzyme active site The NA inhibitors Oseltamivir Zanamivir - Oral, IV(?) - Inhaled, IV(?) - Global - Global Peramivir Laninamivir -IV - Inhaled (single) - Japan, - Japan S.Korea, China, US The NA inhibitors Oseltamivir Zanamivir - Oral, IV(?) - Inhaled, IV(?) - Global - Global • Came on the market in many countries in 2000 after clinical studies had been conducted among influenza virus–infected patients with uncomplicated illness. • Oseltamivir is market leader ……due to ease of oral administration • Use for seasonal influenza mainly in Japan and US • With human infections of highly pathogenic influenza A(H5N1) virus from 2003 with a high case‐fatality risks of >50%, governments began to consider antiviral drug administration as a key component of their pandemic response • suitable vaccines would not be available Stockpiling for a pandemic • Oseltamivir was simpler (oral) administration than zanamivir (inhalation) and because of systemic effect of oseltamivir was expected to be appropriate for treatment of highly pathogenic viruses • Oseltamivir was suddenly in high demand! • Roche had warned that need to stockpile to guarantee availability • Since 2005, governments of middle‐income and high‐income countries around the world have spent billions of dollars (estimated) stockpiling oseltamivir (US Gov. Accounting Office). 2009 A(H1N1)pdm09 pandemic • The first pandemic of the 21st century occurred unexpectedly in 2009 after the global spread of a novel virus—influenza A(H1N1)pdm09—of swine (rather than avian) origin.
    [Show full text]
  • Incubation Period and Other Epidemiological
    Journal of Clinical Medicine Article Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data 1, 1, 1 1 Natalie M. Linton y , Tetsuro Kobayashi y, Yichi Yang , Katsuma Hayashi , Andrei R. Akhmetzhanov 1 , Sung-mok Jung 1 , Baoyin Yuan 1, Ryo Kinoshita 1 and Hiroshi Nishiura 1,2,* 1 Graduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan; [email protected] (N.M.L.); [email protected] (T.K.); [email protected] (Y.Y.); katsuma5miff[email protected] (K.H.); [email protected] (A.R.A.); [email protected] (S.-m.J.); [email protected] (B.Y.); [email protected] (R.K.) 2 Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Honcho 4-1-8, Kawaguchi, Saitama 332-0012, Japan * Correspondence: [email protected]; Tel.: +81-11-706-5066 These authors contributed equally to this work. y Received: 25 January 2020; Accepted: 10 February 2020; Published: 17 February 2020 Abstract: The geographic spread of 2019 novel coronavirus (COVID-19) infections from the epicenter of Wuhan, China, has provided an opportunity to study the natural history of the recently emerged virus. Using publicly available event-date data from the ongoing epidemic, the present study investigated the incubation period and other time intervals that govern the epidemiological dynamics of COVID-19 infections. Our results show that the incubation period falls within the range of 2–14 days with 95% confidence and has a mean of around 5 days when approximated using the best-fit lognormal distribution.
    [Show full text]
  • Medical Terminology Abbreviations Medical Terminology Abbreviations
    34 MEDICAL TERMINOLOGY ABBREVIATIONS MEDICAL TERMINOLOGY ABBREVIATIONS The following list contains some of the most common abbreviations found in medical records. Please note that in medical terminology, the capitalization of letters bears significance as to the meaning of certain terms, and is often used to distinguish terms with similar acronyms. @—at A & P—anatomy and physiology ab—abortion abd—abdominal ABG—arterial blood gas a.c.—before meals ac & cl—acetest and clinitest ACLS—advanced cardiac life support AD—right ear ADL—activities of daily living ad lib—as desired adm—admission afeb—afebrile, no fever AFB—acid-fast bacillus AKA—above the knee alb—albumin alt dieb—alternate days (every other day) am—morning AMA—against medical advice amal—amalgam amb—ambulate, walk AMI—acute myocardial infarction amt—amount ANS—automatic nervous system ant—anterior AOx3—alert and oriented to person, time, and place Ap—apical AP—apical pulse approx—approximately aq—aqueous ARDS—acute respiratory distress syndrome AS—left ear ASA—aspirin asap (ASAP)—as soon as possible as tol—as tolerated ATD—admission, transfer, discharge AU—both ears Ax—axillary BE—barium enema bid—twice a day bil, bilateral—both sides BK—below knee BKA—below the knee amputation bl—blood bl wk—blood work BLS—basic life support BM—bowel movement BOW—bag of waters B/P—blood pressure bpm—beats per minute BR—bed rest MEDICAL TERMINOLOGY ABBREVIATIONS 35 BRP—bathroom privileges BS—breath sounds BSI—body substance isolation BSO—bilateral salpingo-oophorectomy BUN—blood, urea, nitrogen
    [Show full text]
  • Call to Action: the Dangers of Influenza and COVID-19 in Adults
    Call to Action The Dangers of Influenza and COVID-19 in Adults with Chronic Health Conditions October 2020 Experts urge all healthcare professionals to prioritize influenza vaccination to help protect adults with chronic health conditions during the COVID-19 pandemic The recommendations in this Call to Action are based on discussions from an Call to Action August 2020 Roundtable convened by the National Foundation for Infectious The Dangers of Influenza Diseases (NFID). The multidisciplinary and COVID-19 in Adults with group of subject matter experts Chronic Health Conditions explored the risks of co-circulation and co-infection with influenza and SARS-CoV-2 viruses in adults with chronic Overview health conditions from the perspective While every influenza (flu) season is unpredictable, of their specialized areas of medicine the 2020-2021 season is characterized by an and discussed strategies to protect unprecedented dual threat: co-circulation of these vulnerable populations. influenza and the novel coronavirus (SARS-CoV-2) that causes COVID-19. Moreover, there is concern Experts agreed that higher levels of that co-circulation and co-infection with influenza influenza vaccination coverage during and COVID-19 viruses could be especially harmful, the 2020-2021 influenza season could particularly among adults at increased risk of reduce the number of influenza-related influenza-related complications. hospitalizations, helping to avoid Influenza poses serious health risks to adults unnecessary strain on the US healthcare with certain chronic health conditions including system during the COVID-19 pandemic, heart disease, lung disease, and diabetes. The so that healthcare facilities have the increased risk of influenza-related complications capacity to provide care to patients includes the potential exacerbation of underlying with COVID-19.
    [Show full text]
  • Fever / Sepsis
    Fever / Sepsis History Signs and Symptoms Differential · Age · Warm · Infections / Sepsis · Duration of fever · Flushed · Cancer / Tumors / Lymphomas · Severity of fever · Sweaty · Medication or drug reaction · Past medical history · Chills/Rigors · Connective tissue disease · Medications Associated Symptoms · Arthritis · Immunocompromised (transplant, (Helpful to localize source) · Vasculitis HIV, diabetes, cancer) · myalgias, cough, chest pain, · Hyperthyroidism · Environmental exposure headache, dysuria, abdominal pain, · Heat Stroke · Last acetaminophen or ibuprofen mental status changes, rash · Meningitis Adult Contact, Droplet, and Airborne Precautions Temperature Measurement Procedure B / if available Pediatric General Section Protocols IV Procedure IO Procedure I P If indicated If indicated Temperature NO Greater than 100.4 F YES (38 C) If Suspected infection ? B then proceed to Protocol 72A otherwise Proceed to Protocol Exit to 72A Appropriate Protocol Pearls · Recommended Exam: Mental Status, Skin, HEENT, Neck, Heart, Lungs, Abdomen, Back, Extremities, Neuro · Febrile seizures are more likely in children with a history of febrile seizures and with a rapid elevation in temperature. · Patients with a history of liver failure should not receive acetaminophen. · Droplet precautions include standard PPE plus a standard surgical mask for providers who accompany patients in the back of the ambulance and a surgical mask or NRB O2 mask for the patient. This level of precaution should be utilized when influenza, meningitis, mumps, streptococcal pharyngitis, and other illnesses spread via large particle droplets are suspected. A patient with a potentially infectious rash should be treated with droplet precautions. · Airborne precautions include standard PPE plus utilization of a gown, change of gloves after every patient contact, and strict hand washing precautions. This level of precaution is utilized when multi-drug resistant organisms (e.g.
    [Show full text]
  • Influenza: Diagnosis and Treatment
    Influenza: Diagnosis and Treatment David Y. Gaitonde, MD; Cpt. Faith C. Moore, USA, MC; and Maj. Mackenzie K. Morgan, USA, MC Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia Influenza is an acute viral respiratory infection that causes significant morbidity and mortality worldwide. Three types of influ- enza cause disease in humans. Influenza A is the type most responsible for causing pandemics because of its high susceptibility to antigenic variation. Influenza is highly contagious, and the hallmark of infection is abrupt onset of fever, cough, chills or sweats, myalgias, and malaise. For most patients in the outpatient setting, the diagnosis is made clinically, and laboratory con- firmation is not necessary. Laboratory testing may be useful in hospitalized patients with suspected influenza and in patients for whom a confirmed diagnosis will change treatment decisions. Rapid molecular assays are the preferred diagnostic tests because they can be done at the point of care, are highly accurate, and have fast results. Treatment with one of four approved anti-influenza drugs may be considered if the patient presents within 48 hours of symptom onset. The benefit of treatment is greatest when antiviral therapy is started within 24 hours of symptom onset. These drugs decrease the duration of illness by about 24 hours in otherwise healthy patients and may decrease the risk of serious complications. No anti-influenza drug has been proven superior. Annual influenza vaccination is recommended for all people six months and older who do not have contraindications. (Am Fam Physician. 2019; 100:online. Copyright © 2019 American Academy of Family Physicians.) Published online November 11, 2019 BEST PRACTICES IN INFECTIOUS DISEASE Influenza is an acute respiratory infection caused by a negative-strand RNA virus of the Orthomyxoviridae fam- Recommendations from the Choosing ily.
    [Show full text]
  • Case Report Prolonged Shedding of Amantadine- and Oseltamivir- Resistant Influenza A(H3N2) Virus with Dual Mutations in an Immunocompromised Infant
    Antiviral Therapy 2010 15:1059–1063 (doi: 10.3851/IMP1657) Case report Prolonged shedding of amantadine- and oseltamivir- resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant Guillermo Ruiz-Carrascoso1*, Inmaculada Casas1, Francisco Pozo1, Marta González-Vincent2, Pilar Pérez-Breña1 1Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain 2Hospital Infantil Universitario Niño Jesús, Madrid, Spain *Corresponding author e-mail: [email protected] In this study, we report a case of multidrug-resistant contained the substitutions E119V in neuraminidase and influenza A(H3N2) virus isolated from an immunosup- V27A in M2, which produce resistance to oseltamivir and pressed patient with prolonged viral shedding. We also adamantanes, respectively. This is the first report of this describe the genetic characterization of the haemagglu- dual mutation pattern in multidrug-resistant influenza tinin, neuraminidase and M2 influenza genes. The virus A(H3N2) virus. Introduction Influenza, which causes significant morbidity and daily because of neurological toxicity). After receiving mortality in immunocompromised patients, is often fludarabine and melphalan as conditioning therapy, he associated with prolonged viral shedding [1,2] underwent allogenic non-identical peripheral blood regardless of vaccination and antiviral therapy. The transplantation from his mother in May 2005 (day 0). multidrug-resistant influenza viruses, including pan- Total lymphocyte cell (TLC) count prior to transplan- demic A(H1N1) and seasonal A(H1N1) and A(H3N2), tation was 1,340 cells/mm3 (25%). On day 10, fever as reported to date in treated immunocompromised was observed and oxygen therapy was required because patients [1,3–6], have presented the E119V, R292K or of respiratory insufficiency.
    [Show full text]
  • Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
    Review Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines Ekramy E. Sayedahmed 1 , Ahmed Elkashif 1, Marwa Alhashimi 1, Suryaprakash Sambhara 2,* and Suresh K. Mittal 1,* 1 Department of Comparative Pathobiology, Purdue Institute for Immunology, Inflammation and Infectious Disease, Purdue University Center for Cancer Research, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA; [email protected] (E.E.S.); [email protected] (A.E.); [email protected] (M.A.) 2 Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA * Correspondence: [email protected] (S.S.); [email protected] (S.K.M.) Received: 2 August 2020; Accepted: 17 September 2020; Published: 1 October 2020 Abstract: Ever since the discovery of vaccines, many deadly diseases have been contained worldwide, ultimately culminating in the eradication of smallpox and polio, which represented significant medical achievements in human health. However, this does not account for the threat influenza poses on public health. The currently licensed seasonal influenza vaccines primarily confer excellent strain-specific protection. In addition to the seasonal influenza viruses, the emergence and spread of avian influenza pandemic viruses such as H5N1, H7N9, H7N7, and H9N2 to humans have highlighted the urgent need to adopt a new global preparedness for an influenza pandemic. It is vital to explore new strategies for the development of effective vaccines for pandemic and seasonal influenza viruses. The new vaccine approaches should provide durable and broad protection with the capability of large-scale vaccine production within a short time. The adenoviral (Ad) vector-based vaccine platform offers a robust egg-independent production system for manufacturing large numbers of influenza vaccines inexpensively in a short timeframe.
    [Show full text]
  • Post-Typhoid Anhidrosis: a Clinical Curiosity
    Post-typhoid anhidrosis 435 Postgrad Med J: first published as 10.1136/pgmj.71.837.435 on 1 July 1995. Downloaded from Post-typhoid anhidrosis: a clinical curiosity V Raveenthiran Summary family physician. Shortly after convalescence A 19-year-old girl developed generalised she felt vague discomfort and later recognised anhidrosis following typhoid fever. Elab- that she was not sweating as before. In the past orate investigations disclosed nothing seven years she never noticed sweating in any abnormal. A skin biopsy revealed the part ofher body. During the summer and after presence of atrophic as well as normal physical exercise she was disabled by an eccrine glands. This appears to be the episodic rise of body temperature (41.4°C was third case of its kind in the English recorded once). Such episodes were associated literature. It is postulated that typhoid with general malaise, headache, palpitations, fever might have damaged the efferent dyspnoea, chest pain, sore throat, dry mouth, pathway of sweating. muscular cramps, dizziness, syncope, inability to concentrate, and leucorrhoea. She attained Keywords: anhidrosis, hypohidrosis, sweat gland, menarche at the age of 12 and her menstrual typhoid fever cycles were normal. Hypothalamic functions such as hunger, thirst, emotions, libido, and sleep were normal. Two years before admission Anhidrosis is defined as the inability of the she had been investigated at another centre. A body to produce and/or deliver sweat to the skin biopsy performed there reported normal skin surface in the presence of an appropriate eccrine sweat glands. stimulus and environment' and has many forms An elaborate physical examination ofgeneral (box 1).
    [Show full text]